Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is Phase-3 ready and has been evaluated in eleven (11) human clinical trials and over 1,003 individuals.Our mission is to build a company with a foundation of product candidates that significantly improve quality of life and patient outcomes for individuals with cardiorenal diseases.
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla., Sept. 5, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
NEW YORK, Aug. 30, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner)
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
PONTE VEDRA, Fla., Aug. 28, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood